Raphael Pharmaceutical (RAPH) Common Equity (2020 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Common Equity came in at -$1.9 million in Q2 2026, down 79.87% year-over-year from -$9.4 million in Q2 2025, and down 31.54% quarter-over-quarter from -$1.4 million in Q4 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Common Equity (2020 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Common Equity across 7 years of filings, most recently posting -$1.9 million for Q2 2026.
- In Q2 2026, Common Equity fell 79.87% year-over-year to -$1.9 million; the TTM figure through Jun 2026 stood at -$1.9 million (down 79.87% YoY), while the FY2025 annual figure was -$1.4 million, down 93.13% from the prior year.
- Common Equity came in at -$1.9 million for Q2 2026 at Raphael Pharmaceutical, down from -$1.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $118000.0 in Q2 2022 to a low of -$1.9 million in Q2 2026.
- Average Common Equity over 5 years is -$464000.0, with a median of -$103000.0 recorded in 2024.
- Year-over-year, Common Equity surged 134.56% in 2022 and tumbled 1044.44% in 2024.
- Over 5 years, Common Equity stood at $106000.0 in 2022, then advanced by 0.94% to $107000.0 in 2023, then tumbled by 793.46% to -$742000.0 in 2024, then sank by 93.13% to -$1.4 million in 2025, then sank by 31.54% to -$1.9 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were -$1.9 million in Q2 2026, -$1.4 million in Q4 2025, and -$1.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | -1.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.89 Mn |
| Dec 31, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.26 Mn |
| Jun 30, 2025 | -1.05 Mn |
| Mar 31, 2025 | -734,000.00 |
| Dec 31, 2024 | -742,000.00 |
| Sep 30, 2024 | -616,000.00 |
| Jun 30, 2024 | -290,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | -61,000.00 |
| Mar 31, 2023 | -9,000.00 |
| Dec 31, 2022 | 106,000.00 |
| Sep 30, 2022 | -62,000.00 |
| Jun 30, 2022 | 118,000.00 |
| Mar 31, 2022 | 103,000.00 |
| Dec 31, 2021 | 128,000.00 |
| Sep 30, 2021 | -125,000.00 |
| Jun 30, 2021 | 191,000.00 |